Format

Send to

Choose Destination
Nat Rev Immunol. 2018 Dec;18(12):773-789. doi: 10.1038/s41577-018-0066-7.

Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer.

Author information

1
Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK. JonesSA@cardiff.ac.uk.
2
Systems Immunity, University Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK. JonesSA@cardiff.ac.uk.
3
Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia. brendan.jenkins@hudson.org.au.
4
Department of Molecular and Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia. brendan.jenkins@hudson.org.au.

Abstract

The IL-6 family of cytokines consists of IL-6, IL-11, IL-27, IL-31, oncostatin M (OSM), leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1) and cardiotrophin-like cytokine factor 1 (CLCF1). Membership of this cytokine family is defined by usage of common β-receptor signalling subunits, which activate various intracellular signalling pathways. Each IL-6 family member elicits responses essential to the physiological control of immune homeostasis, haematopoiesis, inflammation, development and metabolism. Accordingly, distortion of these cytokine activities often promotes chronic disease and cancer; the pathological importance of this is exemplified by the successful treatment of certain autoimmune conditions with drugs that target the IL-6 pathway. Here, we discuss the emerging roles for IL-6 family members in infection, chronic inflammation, autoimmunity and cancer and review therapeutic strategies designed to manipulate these cytokines in disease.

PMID:
30254251
DOI:
10.1038/s41577-018-0066-7

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center